Benefits of early salvage therapy on oncological outcomes in high-risk prostate cancer with persistent PSA after radical prostatectomy

被引:0
作者
D. Milonas
A. Laenen
Z. Venclovas
L. Jarusevicius
G. Devos
S. Joniau
机构
[1] Lithuanian University of Health Sciences,Medical Academy, Department of Urology
[2] KU Leuven,Leuven Biostatistics and Statistical Bioinformatics Center
[3] Lithuanian University of Health Sciences,Medical Academy, Department of Oncology and Hematology
[4] University Hospitals Leuven,Department of Urology
来源
Clinical and Translational Oncology | 2022年 / 24卷
关键词
Prostate cancer; Radical prostatectomy; PSA persistence; Salvage treatment;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:371 / 378
页数:7
相关论文
共 75 条
[1]  
Moris L(2020)Benefits and risks of primary treatments for high-risk localized and locally advanced prostate cancer: an international multidisciplinary systematic review Eur Urol 77 614-627
[2]  
Cumberbatch MG(2012)Complications and functional results of surgery for locally advanced prostate cancer Adv Urol 2012 209-212
[3]  
Van Den Broeck T(2011)Outcome of surgery in locally advanced pT3a prostate cancer Cent Eur J Urol 64 618-629
[4]  
Joniau SG(2017)EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent Eur Urol 71 106-114
[5]  
Van Baelen AA(2019)Persistent prostate-specific antigen after radical prostatectomy and its impact on oncologic outcomes Eur Urol 76 1142-1148
[6]  
Hsu CY(2016)The role of prostate-specific antigen persistence after radical prostatectomy for the prediction of clinical progression and cancer-specific mortality in node-positive prostate cancer patients Eur Urol 69 37-45
[7]  
Milonas D(2017)Predictive factors and oncological outcomes of persistently elevated prostate-specific antigen in patients following robot-assisted radical prostatectomy J Robot Surg 11 785-791
[8]  
Baltrimavicius R(2019)The impact of prostate-specific antigen persistence after radical prostatectomy on the efficacy of salvage radiotherapy in patients with primary N0 prostate cancer BJU Int 124 239-244
[9]  
Grybas A(2012)Persistently elevated prostate-specific antigen at six weeks after radical prostatectomy helps in early identification of patients who are likely to recur World J Urol 30 288-294
[10]  
Mottet N(2015)Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96–02 trial Int J Radiat Oncol Biol Phys 91 1750-1756